CBLB612 is a preclinical synthetic lipopeptide. It is a toll-like receptor 2 (TLR2) agonist that acts as a powerful inducer and mobilizer of hematopoietic stem cells (HSCs).
Preclinical studies in mice and non-human primates (NHPs) have shown CBLB612 to activate HSCs to a greater degree than marketed biologic agents. These studies have also demonstrated a potent synergistic effect in mice and NHPs when combined with current standards of care.
Cleveland Biolabs is currently considering applications for CBLB612 in patient populations with high unmet medical needs that could most benefit from this novel biologic. Stem cell mobilization is important in many patient populations with cancer.
IND enabling studies are being conducted in preparation for filing an IND in the US.